Dual Antiplatelet Therapy

Abbott announced it received FDA approval, CE mark approval in Europe, and Pharmaceuticals and Medical Devices Agency approval in Japan, and has launched new 4.5 mm and 5 mm stent sizes.

In patients with high bleeding risk who underwent complex PCI, dual antiplatelet therapy for approximately 1 month reduced bleeding compared with slightly longer DAPT duration, according to new data from the MASTER DAPT trial.

WASHINGTON — In the ADAPT-TAVR trial of patients who had transcatheter aortic valve replacement and no indication for long-term anticoagulation, edoxaban did not improve leaflet thrombosis compared with dual antiplatelet therapy.

Commencing long-term dual antiplatelet therapy with cilostazol no less than 15 days after stroke proved to be a stronger method of secondary stroke prevention than standard monotherapy, according to study results published in Neurology.

Magnetically controlled capsule endoscopy to identify gastrointestinal injury in patients taking antiplatelet therapy after PCI.

Ticagrelor monotherapy after 3 months of dual antiplatelet therapy lowered the incidence of major bleeding events vs. continued DAPT among patients with high bleeding risk who underwent PCI, according to new insights from TWILIGHT.

Dual antiplatelet therapy that combined aspirin with either ticagrelor or clopidogrel outperformed aspirin alone in minor ischemic stroke and transient ischemic attack, according to results of a network meta-analysis.

Coronary revascularization confers similar outcomes regardless of race, ethnicity or sex, so decisions on revascularization should be made based on clinical indications, according to a new guideline.

Ticagrelor added to low-dose aspirin reduced the risk for spontaneous MI, MI related to stent thrombosis and STEMI compared with placebo in patients with diabetes and CAD, according to a new analysis of the THEMIS trial.

Healio and Cardiology Today have curated a list of the most-read headlines from TCT 2021.